Duopharma Biotech to produce second oncology medicine


Group managing director Leonard Ariff Abdul Shatar said the HAPI plant would produce various oncology drugs that were clinically proven to fight against many types of cancers.

KUALA LUMPUR: Pharmaceutical firm Duopharma Biotech Bhd, through wholly-owned subsidiary Duopharma HAPI Sdn Bhd, will soon manufacture its second oncology drug at its first-in-Malaysia highly potent active pharmaceutical ingredient (HAPI) Plant in Shah Alam to help address the paucity of affordable alternatives to treat cancer.

Group managing director Leonard Ariff Abdul Shatar said the HAPI plant would produce various oncology drugs that were clinically proven to fight against many types of cancers.

Get 30% off with our ads free Premium Plan!

Monthly Plan

RM13.90/month
RM9.73 only

Billed as RM9.73 for the 1st month then RM13.90 thereafters.

Annual Plan

RM12.33/month
RM8.63/month

Billed as RM103.60 for the 1st year then RM148 thereafters.

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Duopharma Biotech , oncology , cancer , healthcare

   

Next In Business News

Keyfield issues maiden RM200mil sukuk wakalah
Electricity tariff to rise by 14%�from�July�2025
Ringgit strengthens against US dollar as rising oil prices lift sentiment
MYMBN faces temporary suspension of bird’s nest exports to China
TNB shortlisted to develop 500MW solar plant in Kedah under LSS5
CCK Consolidated declares special dividend of 5.0 sen
Santa Claus rally extends on Bursa Malaysia
Alibaba, E-Mart to create US$4bil e-commerce JV in Korea
Oil prices inch up on hopes for more China stimulus
Gold gains on geopolitical turmoil; Fed, Trump's 2025 policies in focus

Others Also Read